Loading
Alzheimer Disease / [F-18]AV-1451-PET · Phase 1 Trial
ClinicalTrials.gov · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a recruiting Phase 1 imaging substudy that has not yet reported results. The study aims to measure tau deposition using [F-18]AV-1451-PET in an Alzheimer's disease cohort and correlate imaging findings to demographic, clinical, genetic, and biomarker variables, with particular attention to race and vascular risk factors. No outcome data are available from this registry record.
Phase 1, Interventional, Single Group, Open label, Diagnostic purpose. Alzheimer Disease; age from 50 Years; accepts healthy volunteers. Intervention: [F-18]AV-1451-PET/MRI. n = 160. 1 site: United States.
This is a recruiting Phase 1 imaging substudy that has not yet reported results. The study aims to measure tau deposition using [F-18]AV-1451-PET in an Alzheimer's disease cohort and correlate imaging findings to demographic, clinical, genetic, and biomarker variables, with particular attention to race and vascular risk factors. No outcome data are available from this registry record.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Results from this imaging substudy, when reported, may help clarify how tau burden measured by AV-1451-PET relates to cognitive status and demographic factors including race and vascular risk in Alzheimer's disease; however, no clinical conclusions can be drawn from this registry record.
This is a recruiting interventional study with no posted results; it is a Phase 1 imaging substudy designed to measure tau deposition and correlate imaging to clinical variables, but outcomes have not yet been reported.
As stated by the source record.
Quoted from the source exactly as published.
Results from this imaging substudy, when reported, may help clarify how tau burden measured by AV-1451-PET relates to cognitive status and demographic factors including race and vascular risk in Alzheimer's disease; however, no clinical conclusions can be drawn from this registry record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT03809351). This is a study registration, not published results. Lead sponsor: University of Alabama at Birmingham. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 160 participants (ESTIMATED). Conditions: Alzheimer Disease. Interventions: DRUG: [F-18]AV-1451-PET. Primary outcome measures: Measurement of pathological tau deposition in the brain. , 5 years. Brief summary: The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing UAB-ADC study. Assessment of interactions between race and vascular risk factors, brain tau levels measured with AV-1451-PET, and cognitive status will be the primary outcome of this imaging study. Individuals participating in this AV-1451-PET/MRI study will also be enrolled in an ongoing \[C-11\]PiB-PET/MRI study (IRB-300001005, IND-138128), and their amyloid, tau and cognitive statuses will be compared in terms of race and vascular risk factors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.